1-羟基-4-苯基-哌嗪 | 87725-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-羟基-4-苯基-哌嗪
• 中文别名: 4-羟基-7-[[[[5-羟基-6-[(4-甲基-3-磺基苯基)偶氮]-7-磺基-2-萘基]氨基]羰基]氨基]-3-(苯偶氮基)萘-2-磺基酸,钠盐
• 英文名称: 4-Phenylpiperazin-1-ol
• 英文别名: 1-hydroxy-4-phenylpiperazine
• CAS: 87725-43-7
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.23
• InChiKey: FIYPCBXQRMGEMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS
  申请人：GE HEALTHCARE LTD

  公开号：WO2011150183A1

  公开（公告）日：2011-12-01

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。
• Photochromic compounds
  申请人：Kumar Anil

  公开号：US20050004361A1

  公开（公告）日：2005-01-06

  Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula —[S 1 ] c -[Q 1 -[S 2 ] d ] d′ -[Q 2 -[S 3 ] e ] e′ -[Q 3 -[S 4 ] f ] f′ —S 5 —P, which is described herein.

  本文披露的各种非限定实施例通常涉及光致变色化合物，可以是热可逆或非热可逆的，并且由此制成的物品。其他非限定实施例涉及光致-二色化合物，可以是热可逆或非热可逆的，并且由此制成的物品。例如，一个非限定实施例提供了一种热可逆的、光致变色化合物，适用于至少具有第一状态和第二状态，其中该热可逆的、光致变色化合物在至少一个状态下的平均吸收比大于2.3，根据CELL METHOD确定。另一个非限定实施例提供了一种光致变色化合物，包括：(a)至少一种从吡喃、噁唑和富里德中选择的光致变色基团；以及(b)连接到至少一种光致变色基团的至少一种延长剂L，由以下公式表示：—[S1]c-[Q1-[S2]d]d′-[Q2-[S3]e]e′-[Q3-[S4]f]f′—S5—P，如本文所述。
• Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
  申请人：LEK Pharmaceuticals d.d.

  公开号：EP2878596A1

  公开（公告）日：2015-06-03

  The present invention provides a new synthetic process for the production of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2-(piperazine-1-yl)phenyl)lithium intermediates.

  本发明提供了一种新的合成工艺，用于生产用于治疗抑郁症和焦虑症的药物1-(2-((2,4-二甲基苯基)硫)苯基)哌嗪（伏地奥西汀），该工艺通过(2-(哌嗪-1-基)苯基)锂中间体进行。
• Substituted Piperidines that Increase P53 Activity and the Uses Thereof
  申请人：Ma Yao

  公开号：US20080004287A1

  公开（公告）日：2008-01-03

  In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein, methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

  在其多种实施形式中，本发明披露了作为HDM2蛋白抑制剂的新型化合物，制备这种化合物的方法，包括一种或多种这种化合物的药物组合物，以及利用这种化合物或药物组合物进行与HDM2蛋白或P53相关的一种或多种疾病的治疗、预防、抑制方法。
• CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS
  申请人：Lee Ki Ho

  公开号：US20120095007A2

  公开（公告）日：2012-04-19

  There is provided a novel carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain (i.e., acute or chronic pain, neuropathic pain, inflammatory pain, diabetic pain, postherpetic neuralgia, etc.), anxiety or depression including an effective amount of the compound, and a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.

  提供了一种新型的卡巴莫氧基芳基烷基哌嗪衍生物化合物，具有丰富的外消旋或对映异构体特性，由式1表示，并提供其药物可用盐或水合物。此外，还提供了一种用于治疗疼痛（即急性或慢性疼痛、神经痛、炎症性疼痛、糖尿病疼痛、带状疱疹后神经痛等）、焦虑或抑郁的药物组合物，包括一定量的该化合物，以及一种通过向需要治疗的哺乳动物投与有效量的该化合物来治疗疼痛、焦虑或抑郁的方法。